company background image
FOLD logo

Amicus Therapeutics NasdaqGM:FOLD Stock Report

Last Price

US$9.59

Market Cap

US$2.9b

7D

0.5%

1Y

-22.8%

Updated

29 Jan, 2025

Data

Company Financials +

Amicus Therapeutics, Inc.

NasdaqGM:FOLD Stock Report

Market Cap: US$2.9b

FOLD Stock Overview

A biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. More details

FOLD fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Amicus Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Amicus Therapeutics
Historical stock prices
Current Share PriceUS$9.59
52 Week HighUS$14.03
52 Week LowUS$8.79
Beta0.61
1 Month Change1.91%
3 Month Change-16.02%
1 Year Change-22.85%
3 Year Change6.32%
5 Year Change-8.80%
Change since IPO-33.54%

Recent News & Updates

Recent updates

Investors Aren't Buying Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Dec 30
Investors Aren't Buying Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Amicus Therapeutics: Cheap Heading Into 2025

Dec 27

Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden

Nov 10
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden

Amicus: Teva Settlement Clears Revenue Path Forward For Galafold

Oct 18

'Boring' Amicus Therapeutics Is Making Progress

Sep 29

Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector

Aug 16

Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Jul 02
Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Jun 06
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Amicus Therapeutics: Too Cheap At Under $10 A Share

May 20

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Mar 27
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Amicus Therapeutics: Expect Improved Commercial Momentum In 2024

Feb 29

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk

Dec 19
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Jul 06
Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

May 14
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

Mar 23
Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Dec 06
We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Aug 25
Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding

Aug 10

Amicus Therapeutics Q2 2022 Earnings Preview

Aug 03

Shareholder Returns

FOLDUS BiotechsUS Market
7D0.5%2.1%-0.2%
1Y-22.8%-3.6%23.7%

Return vs Industry: FOLD underperformed the US Biotechs industry which returned -3.6% over the past year.

Return vs Market: FOLD underperformed the US Market which returned 23.7% over the past year.

Price Volatility

Is FOLD's price volatile compared to industry and market?
FOLD volatility
FOLD Average Weekly Movement4.6%
Biotechs Industry Average Movement11.3%
Market Average Movement6.5%
10% most volatile stocks in US Market18.8%
10% least volatile stocks in US Market3.3%

Stable Share Price: FOLD has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: FOLD's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002517Brad Campbellamicusrx.com

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.

Amicus Therapeutics, Inc. Fundamentals Summary

How do Amicus Therapeutics's earnings and revenue compare to its market cap?
FOLD fundamental statistics
Market capUS$2.89b
Earnings (TTM)-US$104.69m
Revenue (TTM)US$493.67m

5.8x

P/S Ratio

-27.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FOLD income statement (TTM)
RevenueUS$493.67m
Cost of RevenueUS$49.43m
Gross ProfitUS$444.24m
Other ExpensesUS$548.93m
Earnings-US$104.69m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.35
Gross Margin89.99%
Net Profit Margin-21.21%
Debt/Equity Ratio217.8%

How did FOLD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/29 23:56
End of Day Share Price 2025/01/29 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amicus Therapeutics, Inc. is covered by 28 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Michael UlzBaird
Yun ZhongBerenberg